Assessment of the effect of the COVID-19 pandemic on UK HbA1c testing: implications for diabetes management and diagnosis
- 13 October 2021
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 76 (3) , 177-184
Abstract
Aims The COVID-19 pandemic, and the focus on mitigating its effects, has disrupted diabetes healthcare services worldwide. We aimed to quantify the effect of the pandemic on diabetes diagnosis/management, using glycated haemoglobin (HbA1c) as surrogate, across six UK centres. Methods Using routinely collected laboratory data, we estimated the number of missed HbA1c tests for ‘diagnostic’/‘screening’/‘management’ purposes during the COVID-19 impact period (CIP; 23 March 2020 to 30 September 2020). We examined potential impact in terms of: (1) diabetes control in people with diabetes and (2) detection of new diabetes and prediabetes cases. Results In April 2020, HbA1c test numbers fell by ~80%. Overall, across six centres, 369 871 tests were missed during the 6.28 months of the CIP, equivalent to >6.6 million tests nationwide. We identified 79 131 missed ‘monitoring’ tests in people with diabetes. In those 28 564 people with suboptimal control, this delayed monitoring was associated with a 2–3 mmol/mol HbA1c increase. Overall, 149 455 ‘screening’ and 141 285 ‘diagnostic’ tests were also missed. Across the UK, our findings equate to 1.41 million missed/delayed diabetes monitoring tests (including 0.51 million in people with suboptimal control), 2.67 million screening tests in high-risk groups (0.48 million within the prediabetes range) and 2.52 million tests for diagnosis (0.21 million in the pre-diabetes range; ~70 000 in the diabetes range). Conclusions Our findings illustrate the widespread collateral impact of implementing measures to mitigate the impact of COVID-19 in people with, or being investigated for, diabetes. For people with diabetes, missed tests will result in further deterioration in diabetes control, especially in those whose HbA1c levels are already high.Keywords
Funding Information
- National Institute for Health Research (HCS/08/011)
This publication has 28 references indexed in Scilit:
- Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort studyBMJ Open Diabetes Research & Care, 2020
- COVID‐19: Generate and apply local modelled transmission and morbidity effects to provide an estimate of the variation in overall relative healthcare resource impact at general practice granularityInternational Journal Of Clinical Practice, 2020
- Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United StatesJournal of Diabetes Science and Technology, 2020
- Prognostic value of HbA1c for in-hospital and short-term mortality in patients with acute coronary syndrome: a systematic review and meta-analysisCardiovascular Diabetology, 2019
- The frequency of testing for glycated haemoglobin, HbA1c, is linked to the probability of achieving target levels in patients with suboptimally controlled diabetes mellitusClinical Chemistry and Laboratory Medicine (CCLM), 2018
- Reduced Testing Frequency for Glycated Hemoglobin, HbA1c, Is Associated With Deteriorating Diabetes ControlDiabetes Care, 2014
- Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional studyBMJ Open, 2014
- Prediabetes: a high-risk state for diabetes developmentThe Lancet, 2012
- Inappropriate Requesting of Glycated Hemoglobin (Hb A1c) Is Widespread: Assessment of Prevalence, Impact of National Guidance, and Practice-to-Practice VariabilityClinical Chemistry, 2012
- Predicting dysglycaemia in patients under investigation for acute coronary syndromeQJM: An International Journal of Medicine, 2010